J.L. Payen

Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha‐2a plus ribavirin therapy

T. Morin, J. Izopet, C. Renou, 2011, Journal of medical virology.

Acute HCV infection detected in a blood donor by NAT

J. Izopet, J. Coste, J. Schved, 2003, Transfusion.

Does HIV-infection influence the response of chronic hepatitis C to interferon treatment? A French multicenter prospective study. French Multicenter Study Group.

X. Causse, J. Izopet, Y. Bacq, 2000, Journal of hepatology.

Study of the association between major histocompatibility complex class II genes and the response to interferon alpha in patients with chronic hepatitis C infection.

J. Izopet, J. Vinel, M. Abbal, 1999, Human immunology.

Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial.

P. Brousset, J. Selves, M. Attal, 1992, Blood.

Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications.

L. Rostaing, J. Izopet, C. Thalamas, 1998, Journal of the American Society of Nephrology : JASN.

Transmissions of hepatitis C virus during the ancillary procedures for assisted conception.

J. Izopet, J. Parinaud, X. Monroziès, 2000, Human reproduction.

A pharmacokinetic model for alpha interferon administered subcutaneously.

G. Houin, L. Rostaing, J. Izopet, 1999, British journal of clinical pharmacology.